These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33491157)

  • 1. Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States.
    Mougalian SS; Kish JK; Zhang J; Liassou D; Feinberg BA
    Adv Ther; 2021 May; 38(5):2213-2225. PubMed ID: 33491157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
    Chabot I; Zhao Q; Su Y
    Curr Med Res Opin; 2020 Dec; 36(12):2025-2036. PubMed ID: 33044090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting.
    Mougalian SS; Copher R; Kish JK; McAllister L; Wang Z; Broscious M; Garofalo D; Radtchenko J; Feinberg BA
    Cancer Med; 2018 Sep; 7(9):4371-4378. PubMed ID: 30066497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study.
    Ni M; Zhou L; Lu Y; Guo D; Li X; Li L; Zhang L; Chen M; Zhang L; Xu F; Yuan Z; Wang S; Shi Y; Yang A; An X
    BMC Cancer; 2024 Sep; 24(1):1214. PubMed ID: 39350055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
    Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
    Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer.
    Coe F; Misra V; McCabe Y; Adderley H; Woodhouse L; Ayub Z; Wang X; Howell S; Ekholm M
    Breast Cancer Res Treat; 2022 Feb; 191(3):535-543. PubMed ID: 34843027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody-Drug Conjugate Therapy.
    Goyal RK; Zhang J; Davis KL; Sluga-O'Callaghan M; Kaufman PA
    Breast Cancer (Dove Med Press); 2023; 15():855-865. PubMed ID: 38020049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer.
    Goyal RK; Zhang J; Davis KL; Sluga-O'Callaghan M; Kaufman PA
    Breast Cancer Res Treat; 2024 May; 205(1):201-210. PubMed ID: 38310616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.
    Yuan P; Hu X; Sun T; Li W; Zhang Q; Cui S; Cheng Y; Ouyang Q; Wang X; Chen Z; Hiraiwa M; Saito K; Funasaka S; Xu B
    Eur J Cancer; 2019 May; 112():57-65. PubMed ID: 30928806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.
    Dranitsaris G; Gluck S; Faria C; Cox D; Rugo H
    Clin Ther; 2015 Jan; 37(1):134-44. PubMed ID: 25433768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
    Pivot X; Marmé F; Koenigsberg R; Guo M; Berrak E; Wolfer A
    Ann Oncol; 2016 Aug; 27(8):1525-31. PubMed ID: 27177860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
    Jacot W; Heudel PE; Fraisse J; Gourgou S; Guiu S; Dalenc F; Pistilli B; Campone M; Levy C; Debled M; Leheurteur M; Chaix M; Lefeuvre C; Goncalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Courtinard C; Cottu P; Robain M; Mailliez A
    Int J Cancer; 2019 Dec; 145(12):3359-3369. PubMed ID: 31087564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
    Kazmi S; Chatterjee D; Raju D; Hauser R; Kaufman PA
    Breast Cancer Res Treat; 2020 Nov; 184(2):559-565. PubMed ID: 32808239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
    Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
    Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study.
    Oruc Z; Kaplan MA; Geredeli C; Yildirim Sari N; Ozaslan E; Aytekin A; Tamer Elkiran E; Koca S; Dogan M; Turan N; Yuce O; Sevinc A; Ercelep O; Isikdogan A
    J BUON; 2020; 25(2):641-647. PubMed ID: 32521847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
    Aseyev O; Ribeiro JM; Cardoso F
    Expert Opin Pharmacother; 2016; 17(4):589-600. PubMed ID: 26809667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial.
    Krasniqi E; Pizzuti L; Valerio MR; Capomolla E; Botti C; Sanguineti G; Marchetti P; Anselmi E; Tomao S; Giordano A; Ficorella C; Cannita K; Livi L; Meattini I; Mauri M; Greco F; Veltri EM; Michelotti A; Moscetti L; Giotta F; Lorusso V; Paris I; Tomao F; Santini D; Tonini G; Villa A; Gebbia V; Gamucci T; Ciliberto G; Sperduti I; Mazzotta M; Barba M; Vici P
    Int J Med Sci; 2021; 18(10):2245-2250. PubMed ID: 33859534
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
    Maeda S; Saimura M; Minami S; Kurashita K; Nishimura R; Kai Y; Yano H; Mashino K; Mitsuyama S; Shimokawa M; Tamura K;
    Breast; 2017 Apr; 32():66-72. PubMed ID: 28056400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study.
    Pedersini R; Vassalli L; Claps M; Tulla A; Rodella F; Grisanti S; Amoroso V; Roca E; Simoncini EL; Berruti A
    Oncology; 2018; 94 Suppl 1(Suppl 1):10-15. PubMed ID: 30036867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
    Scarpace SL
    Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.